7.87 USD
-0.07 (-0.88%)
7.87 USD
0 (0%)
CDXC gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. CDXC is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. CDXC has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
CDXC had positive earnings in the past year.
In the past year CDXC had a positive cash flow from operations.
CDXC had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: CDXC reported negative operating cash flow in multiple years.
1.2 Ratios
CDXC has a Return On Assets of 12.52%. This is amongst the best in the industry. CDXC outperforms 90.91% of its industry peers.
Looking at the Return On Equity, with a value of 18.55%, CDXC belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
CDXC's Return On Invested Capital of 12.13% is amongst the best of the industry. CDXC outperforms 89.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.52% | ||
| ROE | 18.55% | ||
| ROIC | 12.13% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Profit Margin value of 8.58%, CDXC is doing good in the industry, outperforming 74.55% of the companies in the same industry.
With a decent Operating Margin value of 7.76%, CDXC is doing good in the industry, outperforming 63.64% of the companies in the same industry.
CDXC has a better Gross Margin (61.84%) than 87.27% of its industry peers.
In the last couple of years the Gross Margin of CDXC has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.76% | ||
| PM (TTM) | 8.58% | ||
| GM | 61.84% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CDXC is still creating some value.
Compared to 1 year ago, CDXC has more shares outstanding
The number of shares outstanding for CDXC has been increased compared to 5 years ago.
The debt/assets ratio for CDXC has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 15.46 indicates that CDXC is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 15.46, CDXC belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
CDXC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.46 |
ROIC/WACC1.11
WACC10.97%
2.3 Liquidity
A Current Ratio of 3.57 indicates that CDXC has no problem at all paying its short term obligations.
CDXC's Current ratio of 3.57 is in line compared to the rest of the industry. CDXC outperforms 54.55% of its industry peers.
A Quick Ratio of 3.06 indicates that CDXC has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.06, CDXC is in line with its industry, outperforming 58.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.06 |
3. Growth
3.1 Past
CDXC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 242.86%, which is quite impressive.
The Revenue has grown by 19.17% in the past year. This is quite good.
CDXC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.56% yearly.
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%
3.2 Future
Based on estimates for the next years, CDXC will show a very strong growth in Earnings Per Share. The EPS will grow by 43.55% on average per year.
CDXC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.24% yearly.
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CDXC is valuated quite expensively with a Price/Earnings ratio of 78.70.
Compared to the rest of the industry, the Price/Earnings ratio of CDXC is on the same level as its industry peers.
Compared to an average S&P500 Price/Earnings ratio of 26.92, CDXC is valued quite expensively.
A Price/Forward Earnings ratio of 66.13 indicates a quite expensive valuation of CDXC.
CDXC's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 23.57. CDXC is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.7 | ||
| Fwd PE | 66.13 |
4.2 Price Multiples
61.82% of the companies in the same industry are more expensive than CDXC, based on the Enterprise Value to EBITDA ratio.
65.45% of the companies in the same industry are more expensive than CDXC, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 51.22 | ||
| EV/EBITDA | 66.44 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CDXC has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CDXC's earnings are expected to grow with 43.55% in the coming years.
PEG (NY)4.14
PEG (5Y)N/A
EPS Next 2Y41.63%
EPS Next 3Y43.55%
5. Dividend
5.1 Amount
No dividends for CDXC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.87
-0.07 (-0.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners30.29%
Inst Owner Change0%
Ins Owners0.01%
Ins Owner Change0%
Market Cap611.89M
Revenue(TTM)99.60M
Net Income(TTM)8.55M
Analysts84.44
Price Target9.21 (17.03%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)415%
Min EPS beat(2)341.18%
Max EPS beat(2)488.82%
EPS beat(4)4
Avg EPS beat(4)242.8%
Min EPS beat(4)41.19%
Max EPS beat(4)488.82%
EPS beat(8)8
Avg EPS beat(8)150.17%
EPS beat(12)10
Avg EPS beat(12)102.99%
EPS beat(16)12
Avg EPS beat(16)74.16%
Revenue beat(2)2
Avg Revenue beat(2)6.44%
Min Revenue beat(2)6.07%
Max Revenue beat(2)6.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.35%
Min Revenue beat(4)-9.39%
Max Revenue beat(4)6.81%
Revenue beat(8)4
Avg Revenue beat(8)1.29%
Revenue beat(12)4
Avg Revenue beat(12)-1.38%
Revenue beat(16)5
Avg Revenue beat(16)-2.29%
PT rev (1m)17.21%
PT rev (3m)17.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.77%
EPS NY rev (3m)-2.77%
Revenue NQ rev (1m)-1.81%
Revenue NQ rev (3m)-1.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.7 | ||
| Fwd PE | 66.13 | ||
| P/S | 6.14 | ||
| P/FCF | 51.22 | ||
| P/OCF | 50.53 | ||
| P/B | 13.27 | ||
| P/tB | 13.38 | ||
| EV/EBITDA | 66.44 |
EPS(TTM)0.1
EY1.27%
EPS(NY)0.12
Fwd EY1.51%
FCF(TTM)0.15
FCFY1.95%
OCF(TTM)0.16
OCFY1.98%
SpS1.28
BVpS0.59
TBVpS0.59
PEG (NY)4.14
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.52% | ||
| ROE | 18.55% | ||
| ROCE | 15.35% | ||
| ROIC | 12.13% | ||
| ROICexc | 104.84% | ||
| ROICexgc | 111.73% | ||
| OM | 7.76% | ||
| PM (TTM) | 8.58% | ||
| GM | 61.84% | ||
| FCFM | 11.99% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
F-Score7
Asset Turnover1.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 20.02% | ||
| Cap/Sales | 0.16% | ||
| Interest Coverage | 7726 | ||
| Cash Conversion | 141.79% | ||
| Profit Quality | 139.72% | ||
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.06 | ||
| Altman-Z | 15.46 |
F-Score7
WACC10.97%
ROIC/WACC1.11
Cap/Depr(3y)21.85%
Cap/Depr(5y)22.95%
Cap/Sales(3y)0.27%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A
EBIT growth 1Y237.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year538.3%
EBIT Next 3Y140.93%
EBIT Next 5YN/A
FCF growth 1Y71.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.14%
OCF growth 3YN/A
OCF growth 5YN/A
CHROMADEX CORP / CDXC FAQ
What is the fundamental rating for CDXC stock?
ChartMill assigns a fundamental rating of 6 / 10 to CDXC.
Can you provide the valuation status for CHROMADEX CORP?
ChartMill assigns a valuation rating of 4 / 10 to CHROMADEX CORP (CDXC). This can be considered as Fairly Valued.
Can you provide the profitability details for CHROMADEX CORP?
CHROMADEX CORP (CDXC) has a profitability rating of 6 / 10.
Can you provide the financial health for CDXC stock?
The financial health rating of CHROMADEX CORP (CDXC) is 8 / 10.
What is the expected EPS growth for CHROMADEX CORP (CDXC) stock?
The Earnings per Share (EPS) of CHROMADEX CORP (CDXC) is expected to grow by 19% in the next year.